Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of -195.10% is 65% above its 5-year average of -561.11%, near the high end of its 5-year range (-45826.00%–451.74%).
47.40% below its 12-month average of -132.36%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
-195.10%
GROSS MARGIN AVG TTM
-132.36%
GROSS MARGIN AVG 3Y
1.72%
GROSS MARGIN AVG 5Y
-561.11%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-47.40%
CURRENT VS 3Y AVG
-11456.16%
CURRENT VS 5Y AVG
+65.23%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-573.49%
vs the sector median at left
Shattuck Labs, Inc.
Market Cap
$529.58M
Gross Margin
-195.10%
TTM Avg
-132.36%
3Y Avg
1.72%
5Y Avg
-561.11%
Market Cap
$531.52M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$531.98M
Gross Margin
87.05%
TTM Avg
84.77%
3Y Avg
78.39%
5Y Avg
75.97%
Market Cap
$533.04M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$524.43M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$538.01M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
50.00%
5Y Avg
33.33%
Market Cap
$519.25M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
31.77%
Market Cap
$516.76M
Gross Margin
73.28%
TTM Avg
79.19%
3Y Avg
65.08%
5Y Avg
51.90%
Market Cap
$548.51M
Gross Margin
82.92%
TTM Avg
86.33%
3Y Avg
62.04%
5Y Avg
41.36%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | $529.58M | -195.10% | -132.36% | 1.72% | -561.11% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $531.52M | 0.00% | 0.00% | 0.00% | 0.00% |
| Delcath Systems, Inc. (DCTH)vs › | $531.98M | 87.05% | 84.77% | 78.39% | 75.97% |
| Monopar Therapeutics Inc. (MNPR)vs › | $533.04M | 0.00% | 0.00% | 0.00% | 0.00% |
| Immix Biopharma, Inc. (IMMX)vs › | $524.43M | 0.00% | 0.00% | 0.00% | 0.00% |
| ProKidney Corp. (PROK)vs › | $538.01M | 100.00% | 100.00% | 50.00% | 33.33% |
| Altimmune, Inc. (ALT)vs › | $519.25M | 100.00% | 100.00% | 100.00% | 31.77% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $516.76M | 73.28% | 79.19% | 65.08% | 51.90% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $548.51M | 82.92% | 86.33% | 62.04% | 41.36% |
| 908 Devices Inc. (MASS)vs › | $505.87M | 49.79% | 48.93% | 50.95% | 52.39% |
Gross Margin
-195.1%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | -661.80% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 68.20% |
| 2024-06-30 | 40.21% |
| 2024-03-31 | 12.65% |
| 2023-12-31 | -37.39% |
| 2023-09-30 | -3429.30% |
| 2023-06-30 | -9002.50% |
| 2023-03-31 | -29140.35% |
| 2022-12-31 | -5332.56% |
| 2022-09-30 | -8797.17% |
| 2022-06-30 | -45826.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 46.12% |
| 2021-09-30 | -696.68% |
| 2021-06-30 | 451.74% |
| 2021-03-31 | -355.37% |
| 2020-12-31 | -629.28% |
| 2020-09-30 | -384.76% |
| 2020-06-30 | -143.79% |
| 2020-03-31 | -173.42% |
| 2019-12-31 | -210.92% |
| 2019-09-30 | -345.35% |
| 2019-06-30 | -136.69% |
| 2019-03-31 | -136.69% |
